About ImmuneMed Inc.
ImmuneMed, Inc. is specialized to diagnose and treat the infectious diseases using antibody and antigen discovery technologies. ImmuneMed Inc. believes that the human immune system itself is the most effective defence system of our body in curing various infectious diseases. These beliefs have been a guiding principle for the company's research over the years. Using the innate immune system, a new antiviral therapeutic has been discovered and developed an endogenous broad-spectrum antiviral drug candidate called Virus suppressing factor (VSF).
ImmuneMed has been further developing VSF to humanized VSF (hzVSF) as an immunoglobulin. ImmuneMed has demonstrated the potential of hzVSF in a series of pre-clinical tests including Hepatitis B & C virus and Influenza A virus in vitro and in vivo using several animal models. ImmuneMed did toxicological test for hzVSF and has planned to manufacture GMP drug product of hzVSF in Lonza. Now ImmuneMed expects to enter a phase 1 clinical trial in 2017 in South Korea. In addition, ImmuneMed has been developed the rapid diagnostic kits using lateral flow immunochromatographic assay for early detection of acute febrile illnesses. Now ImmuneMed are developing diagnostic kits including Dengue Haemorrhagic Fever, Typhoid Fever and etc. ImmuneMed has been holding ambitions which contribute to human health to be free from infectious diseases since it was founded in 2000.
State of Ownership
Business Development Associate Director, University of Michigan
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature